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Abstract 
Over the last four years, the Lipid-Calcium-Phosphate (LCP) nanoparticle platform has shown 
success in a wide range of treatment strategies, recently including theranostics. The high specific 
drug loading of radiometals into LCP, coupled with its ability to efficiently encapsulate many types 
of cytotoxic agents, allows a broad range of theranostic applications, many of which are yet 
unexplored. In addition to providing an overview of current medical imaging modalities, this review 
highlights the current theranostic applications for LCP using SPECT and PET, and discusses 
potential future uses of the platform by comparing it with both systemically and locally delivered 
clinical radiotherapy options as well as introducing its applications as an MRI contrast agent. 
Strengths and weaknesses of LCP and of nanoparticles in general are discussed, as well as caveats 
regarding the use of fluorescence to determine the accumulation or biodistribution of a probe. 
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Introduction 
The fields of tumor imaging and cancer therapy 
have been steadily sliding closer together since the 
field recognized a need for targeted therapeutics. 
Targeted delivery must be coupled with verification 
of payload deposition in order to effectively monitor 
and analyze therapeutic outcomes. A wealth of 
theranostic agents have been developed to address 
the growing desire for this dual-purpose paradigm, 
and nanoparticle formulations have recently come to 
the forefront of theranostic research1, 2.  
Calcium phosphate precipitates have been used 
as in vitro transfection agents since the 1970s3, when it 
was discovered that DNA could be co-precipitated in 
a solution containing calcium chloride and 
phosphate-buffered saline. Since that time, there has 
been a substantial effort to control particle size and 
aggregation in order to increase transfection efficiency 
and allow delivery in vivo. Some formulation 
strategies gained moderate success in vitro4-6, but it 
was not until 2010 that calcium phosphate 
nanoparticles were successfully coated with a lipid 
bilayer7, and not until 2012 that these so-called 
Lipid-Calcium-Phosphate (LCP) nanoparticles 
showed efficient gene silencing in vivo8. Since that 
time, the two seminal papers have garnered nearly 
300 citations, inspiring many other laboratories to use 
LCP themselves or innovate on its design9-14. The 
Huang lab has published nearly 20 original research 
articles using LCP, due to its versatility in 
encapsulating many types of therapeutic compounds, 
such as small molecule drugs15-17, siRNA18-22, DNA23, 
peptides24, and radionuclides25, 26. The principles 
behind LCP formulation have also allowed the Huang 
lab to formulate lipid-coated nanoparticles with cores 
entirely made of cisplatin27, 28. Over the last six years, 
LCP has transitioned from a novel formulation to a 
powerful tool used to probe for answers regarding 
PEGylation kinetics29, the tumor microenvironment15, 
18, 24, 25, cancer vaccines18, 24, and gene therapy23. The 
Huang lab has now begun using LCP as a theranostic 
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agent, using imaging modalities such as SPECT and 
PET.  
LCP is formulated using a reverse (water-in-oil) 
microemulsion system. In separate round-bottom 
flasks, water droplets containing either calcium or 
phosphate are stirred in an oil phase containing 
cyclohexane and the surfactant igepal. The surfactant 
maintains the oil-water interface and stabilizes 
nano-sized water droplets in the oil. When the two 
emulsions are mixed and the separate droplets 
collide, the soluble calcium and phosphate react to 
form nanoprecipitates, still suspended in the water 
droplets. Addition of the phospholipid DOPA soon 
after mixing allows the formation of a single lipid 
layer at the oil-water interface in which the 
hydrophilic head of DOPA inserts inside the water 
droplet and its hydrophobic tail remains in the oil 
phase. The phosphate head group of the DOPA 
co-precipitates into the calcium-phosphate 
nanoprecipitate, positioning the hydrophobic tail to 
remain in the oil. Over time, the co-precipitated 
DOPA replaces more and more igepal in the water-oil 
interface, and eventually the calcium phosphate 
precipitates are so well coated with DOPA that they 
are able to be dissolved in organic solvents such as 
chloroform or dichloromethane after washing with 
ethanol. The final LCP nanoparticle, shown in Figure 
1, is generated by adding free lipids such as DOTAP, 
cholesterol, and DSPE-PEG2000, also in organic 
solvent, to the cores. The solvent is then evaporated to 
leave a thin film of lipids and cores on the edge of the 
vial. Addition of warm water/sucrose solution and 
brief sonication is all that is needed to resuspend the 
final particles for testing or injection into mice.  
Encapsulation of therapeutics into LCP occurs 
during the calcium-phosphate nanoprecipitation 
portion of the procedure. Phosphorylated prodrugs, 
nucleotide mimics, siRNA, and DNA are all ideal 
candidates for encapsulation into LCP because the 
phosphate groups on all of these molecules will 
co-precipitate in the calcium-phosphate LCP core. 
Radionuclides such as indium and lutetium can 
similarly be encapsulated via their low solubility with 
phosphate. Because calcium-phosphate is acid- 
sensitive, after the LCP is delivered to the cellular 
endosome, the late endosome’s acidic environment 
will dissolve the calcium-phosphate core7. The 
increase in endosomal salt concentration increases the 
osmolarity in the endosome, destabilizing it and 
releasing the therapeutics into the cytosol. The cell 
avoids calcium-induced toxicity by quickly lowering 
cytosolic calcium via the mitochondrial calcium 
uniporter and then by more slowly removing the 
excess intracellular calcium via the plasma membrane 
calcium ATPase30. 
 
 
 
Figure 1: Schematic of LCP nanoparticle synthesis. LCP is capable of encapsulating siRNA, mRNA, DNA, phosphorylated peptides, nucleotide mimics, and radioactive isotopes 
in its calcium phosphate core. Source: Adapted from Satterlee et al25. Copyright © 2015 Elsevier B.V. License number: 3815560646760 
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Herein we aim to review current imaging 
techniques and compare the theranostic capabilities of 
LCP to clinical practices that combine therapy and 
imaging. This review will focus its discussion on the 
nuclear imaging modalities SPECT and PET. 
Single Photon Emission Computed 
Tomography (SPECT) 
SPECT imaging detects γ photon emissions from 
a decaying radioactive source inside the body31. 
Radionuclides with a high abundance of γ decay at 
energies around 100-200 keV32, such as 111In, 99mTc, 
and 123I, are ideal for detection using SPECT, as their γ 
energies are high enough to avoid attenuation in 
tissue but low enough to be adequately captured by 
the SPECT detectors. Because the source emits 
photons in all directions, in order to maximize spatial 
resolution, a collimator must be used to block all 
photons that are not approaching the detector from 
the region or angle of interest. More selective 
collimators increase the resolution of the image but 
also reduce signal to the detectors, requiring longer 
detection times or higher doses of radionuclide to 
maintain adequate image reconstruction33. SPECT is 
often run in combination with a computed 
tomography (CT) scan to provide anatomical contrast.  
Positron Emission Tomography (PET) 
PET imaging is similar to SPECT imaging, as the 
PET detectors also detect γ photons from a radioactive 
source inside the body32. In contrast to SPECT, the 
photons detected in PET are generated from an 
annihilation reaction between a positron emitted by 
the source and a nearby electron present in the body. 
The annihilation reaction converts the 
electron-positron pair into 511 keV photons that travel 
in opposite directions toward the PET detector. By 
only counting photon pairs that are detected at a 180o 
angle from each other, all other noise not attributed to 
positron emission can be disregarded, eliminating the 
need for collimation. By also calculating the small 
differences in detector arrival time of the photon 
pair—referred to as time-of-flight—, more accurate 
spatial localization of the radionuclide can be 
determined34. The unique imaging properties of 
positron emitters allow PET imaging to be more 
sensitive than SPECT, but PET must also be coupled 
with an imaging modality like CT or MRI for 
anatomical contrast. 
Comparing two common PET agents, copper-64 
(64Cu) and gallium-68 (68Ga), will demonstrate the 
additional considerations that must be made when 
planning a PET imaging study. Half-life must first be 
considered, as many PET agents have very short 
half-lives and must be produced and purified on-site. 
64Cu has a relatively long half-life of 12.7 h, allowing it 
to be shipped overnight without decaying 
prohibitively, unlike 68Ga which has a half-life of just 
68 minutes. Fortunately, 68Ga is generated by the slow 
decay of Germanium-68 (68Ge) and can be quickly 
purified from its parent on-site35, unlike 64Cu which 
must be generated by neutron or proton 
bombardment in a nuclear reactor or cyclotron36. 
Half-life also affects the total dose of nuclide that must 
be given to achieve the same decay rate during 
imaging. It is desirable to inject a low total dose with a 
high rate of decay such that a large portion of the 
decay will occur during the imaging experiment. In a 
one-hour PET imaging session using 68Ga, half of the 
remaining 68Ga atoms will decay during the imaging 
experiment, but if 64Cu is used, less than 10% of the 
64Cu will decay during the experiment, leaving the 
rest to decay over the next few days. In order to 
produce the same quality image, both 64Cu and 68Ga 
need to be dosed at similar positron decay rates, and 
since 68Ga decays more quickly, fewer total atoms also 
need to be given, further lowering the required dose.  
The energy with which a positron is emitted, 
β+max = 653 keV for 64Cu and β+max = 1899 keV for 68Ga, 
also affects the resolution of the image. A positron 
must be at rest energy before annihilating with an 
electron, and any extra energy is released as the 
positron proceeds away from its parent nucleus and 
collides with other matter37. Positrons ejected at 
higher energies must release more energy before 
annihilation and therefore must travel further away 
from the nucleus before the resulting two γ photons 
are generated. Because the PET detectors can only 
detect where in space the photons were generated, 
and not where the positron was emitted, a longer 
positron range will generate larger areas between the 
positron emitter and the photon generation, thus 
decreasing the spatial resolution of the image. The 
average positron ranges in water for 64Cu and 68Ga are 
0.55 mm and 2.8 mm, respectively38, which is not a 
negligible difference and should be considered when 
planning an experiment.  
Clinical Nuclear Imaging 
In the clinic, SPECT and PET contrast agents are 
often used diagnostically for blood vessel perfusion 
imaging or tumor diagnosis. Radiometals have 
recently seen more use in the clinic, and are often 
chelated to small molecules or targeted proteins. A 
huge amount of effort has gone into discovering 
bifunctional chelators that stably bind both the 
radiometal and the tumor-targeting moiety39-43. 
Because each radiometal ion can differ in atomic size, 
oxidation state, and electron configuration, a chelator 
that stably binds one metal may not be suitable for 
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another. Stability tests must include exposing the 
chelated metal to serum conditions, as an inadequate 
chelator may have higher affinity for an endogenous 
metal ion or allow reduction of its metal into a less 
stable state44. The expected circulation time of the 
radionuclide must also be considered, as a nuclide 
chelated to a protein with a circulation half-life on the 
order of days would need a much more stable 
chelator than one on a particle with a half-life of an 
hour or less. If an unsuitable chelator is chosen to bind 
a radionuclide, the nuclide may prematurely shed in 
circulation and skew the biodistribution data, as 
highly charged heavy metals such as 111In(III) or 
177Lu(III) prefer to accumulate in the bone, and 
actively metabolized metals such as copper may be 
filtered through the liver and into the intestines.  
There are several typical radioisotopes used 
diagnostically as SPECT and PET contrast agents. 
Current clinical uses involve chelation or conjugation 
of the isotopes to small molecules for blood vessel 
perfusion imaging or tumor diagnosis. Classically, the 
γ emitter 99mTc has been injected intravenously into 
patients after chelation to one of several small 
molecules such as exametazime and sestamibi45. The 
lipophilic conjugate formed can accumulate in tumors 
and allow detection of many types of cancer via 
SPECT. In several clinical trials, 99mTc has also been 
conjugated to the apoptosis marker Annexin V to 
gauge a patient’s response to treatment46. A similar 
agent exists for PET imaging. Incorporation of the 
positron emitter 18F as the 2’ group on glucose 
molecules yields 18Fluoro-deoxyglucose (18FDG), 
which can accumulate in tumors due to a tumor’s 
high glucose uptake and the inability for cells to 
metabolize FDG after uptake. 111In is also currently 
used as a diagnostic agent to measure tumor burden 
or metastasis by chelating it to an antibody targeted to 
an overexpressed tumor receptor47. The clinically 
used ProstaScint® is an 111In-conjugated monoclonal 
antibody against prostate specific membrane antigen 
used to diagnose prostate cancer. In some cases, such 
as in the phase II clinical trial for a doxorubicin-linked 
polymeric micelle termed PK1, pharmacokinetics and 
biodistribution of the micelle were determined by 
conjugating the γ emitter 123I onto a small amount of 
PK1 analog during one treatment cycle48. The imaging 
analog contained an additional methacryloyltyro-
sinamide group whose tyrosine moiety was labeled 
with 123I via the Iodogen® labeling procedure49. These 
imaging strategies have laid the groundwork for those 
therapeutics that can simultaneously image and treat 
the tumor.  
Radioimmunotherapy 
Another recent effort has been placed on 
formulations that can accumulate in the tumor to 
provide diagnosis while simultaneously treating the 
tumor mass, and so far the most successful 
radio-theranostics in the clinic seem to be those used 
in radioimmunotherapy (RIT). RIT is a treatment 
strategy in which a therapeutic radioisotope such as 
90Y or 177Lu is chelated and covalently bound to an 
antibody that will selectively target the tumor. 90Y has 
a higher β energy and a longer β range in tissue, while 
177Lu decays via both β and γ emission, allowing 
SPECT imaging with simultaneous therapy. The 
radioimmunotherapeutic Zevalin®, which uses 90Y, 
was the first in its class to receive FDA approval and is 
currently seeing success in the clinic50. Zevalin® is 
used against Non-Hodgkin’s Lymphoma (NHL) and 
uses the murine anti-CD20 antibody Ibritumomab 
against B-cells as a targeting and therapeutic agent. 
Unfortunately, the antibodies used in this therapy are 
known to cause sometimes serious toxicity via 
complement activation and subsequent cytokine 
release51-53. Antibodies used in RIT are also very 
expensive, especially those that have been humanized 
or otherwise modified to reduce toxicity.  
An effective alternative to RIT may be to use a 
peptide instead of an antibody to target the chelated 
radionuclide to the tumor, which would be less toxic 
and less expensive. This approach has been termed 
Peptide Receptor Radionuclide Therapy (PRRT) and 
the most successful designs have used a somatostatin 
analog called octreotate to target the somatostatin 
receptor overexpressed in neuroendocrine tumors54-56. 
The novel molecule DOTA-TATE (Figure 2) was 
generated by covalently linking the chelator DOTA to 
octreotate, allowing chelation of radionuclides such as 
177Lu, 90Y, 64Cu, and 111In for imaging and therapy. 
PRRT with octreotate was recently approved by the 
FDA for use in patients with neuroendocrine cancer. 
The dual therapy (β) and imaging (γ) capabilities of 
177Lu allow simultaneous treatment and dosimetry of 
patients receiving 177Lu-DOTA-TATE57. The absorbed 
dose to healthy organs, especially the kidneys and 
bone marrow, was calculated from γ-scintigraphy and 
SPECT/CT images in order to provide the maximum 
therapeutic dose without exceeding the maximum 
acceptable dose to healthy tissue.  
SPECT Imaging with LCP 
The LCP formulation procedure allows efficient 
encapsulation of radiometals without the use of a 
chelator, and as of 2015, two articles have been 
published using LCP for SPECT imaging. The first 
encapsulated the γ emitter 111In3+ into the core of LCP 
as an imaging agent to measure lymph node 
accumulation of LCP, initiating research on treating 
lymph node metastasis26. The second article 
 Theranostics 2016, Vol. 6, Issue 7 
 
http://www.thno.org 
922 
encapsulated the γ and β emitter 177Lu3+ as both an 
imaging and therapeutic agent25. It was discovered 
that the 3+ charge on radiometals like 177Lu enabled 
very selective encapsulation in the LCP core, as their 
solubility product with phosphate are many orders of 
magnitude lower than that of calcium and phosphate 
(ksp lutetium-phosphate = 2x10-25; ksp 
calcium-phosphate = 1x10-7). Consequently, when 
177Lu was co-precipitated into the LCP core, a 70% 
encapsulation efficiency of 177Lu was maintained as 
the feed ratio of lutetium to calcium was increased by 
four orders of magnitude, allowing a tunable loading 
of radionuclide in a single-sized batch of LCP. 
Because only a trace amount of 177Lu is required to 
provide therapeutic effect, small-scale batches are still 
sufficient to produce 177Lu-LCP particles at 
human-level therapeutic dosing. Even at the highest 
stable feed ratio of Lu:Ca, 177Lu-LCP maintains its 
encapsulation efficiency and morphology in particles 
that are still overwhelmingly composed of calcium 
phosphate (1:1000 Lu:Ca input ratio). This eliminates 
the risk of heavy metal toxicity that would be 
presented in neutron-activatable theranostic 
nanoparticles, which can be loaded with as much as 
20 wt% of the heavy metal ion58. In this case, the 
nanoparticles are bombarded with neutrons in a 
nuclear reactor to produce radioactive 166Ho from 
stable 165Ho. Only a small fraction of the 165Ho is 
converted, increasing the dose of nanoparticles and 
heavy metal that must be given, but this method does 
decrease radioactive handling during fabrication. 
177Lu has a max β energy of ~500 keV and γ 
energies of 113 and 208 keV. The γ energies are in the 
ideal range for efficient SPECT imaging and allow the 
biodistribution and tumor accumulation of 177Lu-LCP 
to be measured using SPECT/CT (Figure 3A) and γ 
scintillation25. The therapeutic β emission from 
177Lu-LCP was found to cause significant tumor 
inhibition via DNA damage-induced H2AX 
phosphorylation, followed by cellular apoptosis. A 
change in the tumor microenvironment’s stromal 
structure was also detected, resulting in a decrease in 
fibroblast and collagen organization. Furthermore, the 
cytotoxic β emission from 177Lu also induced photons 
in the visible spectrum from the surrounding media. 
This Cerenkov radiation is generated from the β 
electron moving faster than the speed of light in tissue 
and was detected using optical imaging in a live 
mouse (Figure 3B). Although Cerenkov imaging does 
not provide a 3D reconstruction of biodistribution as 
SPECT does, it does allow less expensive and faster 
image acquisition that would be especially useful in 
determining early biodistribution kinetics using 
multiple scans in quick succession. Cerenkov 
radiation also allows imaging of other β-emitting 
nuclides such as 90Y that would otherwise not be 
available for imaging studies.  
 
 
Figure 2: Chemical Structure of the PRRT agent 177Lu-DOTA-TATE 
 
 
Figure 3: (A) SPECT/CT and (B) Cerenkov imaging of a live athymic nude mouse 
bearing a subcutaneous UMUC3/3T3 stroma-rich bladder cancer tumor at t = 24 h 
after i.v. injection of 2.5 mCi of 177Lu-LCP. Tumor accumulation of 177Lu is clearly 
visible above background, although not as high as liver and spleen accumulation. 
SPECT and Cerenkov agree on the overall biodistribution of 177Lu. Source: Adapted 
from Satterlee et al25. Copyright © 2015 Elsevier B.V. License number: 
3815560646760 
 
Local Delivery of Radiation Therapy 
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from the body through the kidneys, and therefore 
tend to accumulate in the body’s other clearing 
organs, which are primarily the liver and spleen. 
Splenocytes and the liver’s Kupffer cells will 
internalize these nanoparticles and attempt to 
metabolize the contents59, so when delivering 
therapeutic siRNA or DNA, this off-target delivery is 
not of much consequence. Additionally, since siRNA 
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therapy often seeks to reintroduce a lost or 
downregulated gene that is present in healthy cells, 
off-target effects resulting from delivery to 
hepatocytes or other healthy cells are dampened. In 
contrast, when radiation is delivered, the cytotoxic 
decay products can reach several millimeters away 
from the delivered source, indiscriminately acting on 
healthy and cancerous cells alike. Although cancer 
cells are more susceptible to DNA damage due to 
their increased proliferation rate and decreased DNA 
repair capacity, care must be taken to minimize the 
dose to off-target organs. Thus, current internal 
radiation therapies focus on local delivery of the 
radiation in order to increase the absorbed dose to the 
tumor and limit dose to healthy tissues. 
Brachytherapy  
Brachytherapy is a type of clinical radiotherapy 
in which the therapeutic radioactive source is 
permanently or temporarily placed in or near the 
tumor site. The majority of brachytherapy procedures 
are performed in prostate cancer, and placement of 
the source(s) is pre-planned using transrectal 
ultrasound to maximize dose to the tumor while 
minimizing dose to healthy tissue, allowing safe dose 
escalation to nearly double that for external beam 
radiation therapy60. In high dose rate (HDR) 
brachytherapy, sealed sources of Iridium-192 are 
temporarily placed within the prostate via 
intraperineal catheterization, while in low dose rate 
(LDR) brachytherapy, sealed radioactive seeds 
measuring ~0.8 mm x 4.5 mm are permanently 
deposited at precise intervals in the prostate. The 
radioisotopes Cesium-131, Iodine-125, and 
Palladium-103 are preferred for LDR brachytherapy 
because their low-energy emissions provide rapid 
dose fall-off with increasing distance from the source, 
minimizing off-target dose61. To decrease incidence of 
seed movement or loss, each row of seeds can be 
sutured together to create a strand of several seeds62. 
LDR seeds are typically placed 1 cm apart63, which 
allows a tunable dose to different areas of the prostate 
based on the activity encapsulated in each seed.  
The new concept of nanobrachytherapy is 
currently limited to simple intratumoral injection of 
radioactive nanoparticles64, but there may be some 
value in delivering nanoparticles that can evenly 
diffuse within the tumor. Major difficulties would be 
in reproducible dosimetry and clearance of the 
nanoparticles out of the tumor, as clearance would 
affect dosimetry as well as convey off-target toxicity 
to the clearing organ. In order to control diffusion and 
minimize clearance, nanoparticle penetration through 
tissue could be tuned by modifying their charge and 
PEGylation density. Highly loaded 177Lu-LCP may be 
a good probe to quantify nanoparticle diffusion and 
clearance in the tumor, both by live animal imaging 
and in frozen tissue sections. In its current 
formulation, LCP may be too acid-sensitive to ensure 
minimal clearance of the radioisotope over the initial 
decay of the delivered isotope, but a similar 
precipitate with a lower ksp such as Cu(PO4) may 
more effectively resist dissolution while maintaining 
the preferential encapsulation of trivalent 
radiometals. Interestingly, excess cellular copper is 
known to generate reactive oxygen-dependent DNA 
damage, which could itself provide an effective 
combination therapy with the delivered radionuclide. 
Selective Internal Radiation Therapy (SIRT) 
SIRT is another clinically approved local 
delivery method for internal radiation therapy. This 
approach delivers radioactive microspheres loaded 
with 90Y to the liver via a surgically implanted 
catheter that is fed up the hepatic artery. It is known 
that while the portal vein provides the majority of the 
blood supply to healthy hepatocytes in the liver, liver 
tumors are fed by the hepatic artery. Thus, 
introduction of microspheres through the hepatic 
artery selectively target the tumor regions. 
Commercially available microsphere formulations 
such as Sir-Spheres by Sirtex are approximately 30 μm 
in diameter, which prevent cellular uptake and deep 
tumor penetration, but also help retain the 
microspheres around the tumor site while minimizing 
clearance through the hepatic capillaries. SIRT is 
currently in several phase II and III clinical trials for 
use in combination with front-line chemotherapeutics 
against hepatocellular carcinoma (HCC) and 
advanced metastatic colorectal cancer65, 66. The data 
from recent clinical trials show that 90Y-SIRT + 
systemic chemotherapy provides significantly more 
hepatic progression-free survival than chemotherapy 
alone while maintaining tolerable liver and lung 
toxicity. 
Although local hepatic delivery using 
90Y-microspheres for SIRT has shown success, there 
are areas in which it can be improved. Most notably, 
the lack of tumor penetration by the microspheres 
requires a high-energy β emitter with a long depth of 
penetration to reach the deeper tumor tissue. To 
maximize the absorbed dose to deep tumor cells, a 
large dose must be provided at the tumor periphery, 
which increases toxicity to healthy liver tissue. A 
future 177Lu-LCP-SIRT therapy may be able to address 
these issues. With a diameter of just 40-60 nm, the 
much smaller 177Lu-LCP could penetrate much deeper 
into the tumor mass, and the addition of an 
appropriate targeting ligand would allow selective 
uptake of the particles into the tumor cells themselves, 
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bringing the radioactive payload closer to the target 
DNA in the cell nucleus. The lower energy and 
shorter depth of penetration of 177Lu’s β emissions 
may then be adequate to treat the entire tumor at a 
lower total dose and with less toxicity to nearby 
healthy tissue, although the efficacy of 177Lu as the 
encapsulated radionuclide should be compared with 
90Y. If 177Lu-LCP is effective, the γ decay from 177Lu 
could then allow simultaneous confirmation of 
177Lu-LCP accumulation in the tumor mass via SPECT 
imaging. Additionally, 177Lu-LCP could be easily 
co-loaded with a phosphorylated chemotherapeutic 
for localized chemoradiation therapy.  
The much smaller size of LCP compared to 
Sir-Spheres also presents new challenges regarding 
the clearance of 177Lu away from the tumor site, not 
only from those particles that are injected into the 
hepatic artery and do not enter the tumor mass, but 
also from any radiation that initially enters the tumor 
and exits at a later time. To ensure maximal tumor 
accumulation and minimal clearance of 177Lu-LCP 
through the vena cava, simple changes to the surface 
of the particle should be made to encourage 
interaction with the tumor cell membrane and 
increase receptor-mediated endocytosis, such as 
modifying the outer leaflet with cationic lipids, 
lowering the surface PEG density, and adding a high 
affinity targeting ligand. Peptide targeting ligands 
may be the most successful class of ligand for this 
purpose, as they generally bind with higher affinity 
than small molecule ligands, and are less bulky, 
expensive, and immunostimulatory than antibodies. 
Peptide ligands against the α6β1 receptor 
overexpressed in human colon cancer cells may be 
successful against liver metastasis67, 68, and similarly, 
overexpression of glypican-3 (GPC-3) in HCC has 
allowed synthesis and use of targeted peptides69, 70. 
Changes in the nanoparticle injection speed should 
also be considered, as a slower infusion of particles 
into the tumor will avoid saturation of the 
surrounding blood vessels and tumor cell receptors. 
The introduction of novel nanodelivery approaches 
does indeed present new challenges in local delivery 
of radioisotopes, but the advantages posed by these 
new methods should make overcoming these 
challenges a worthwhile venture. 
Original Research: PET Imaging with LCP 
The successful encapsulation of 177Lu and 111In in 
the LCP core25, 26 prompted experiments to 
encapsulate a radionuclide into an LCP formulation 
already containing chemotherapeutics in order to 
better study its kinetics and biodistribution. The LCP 
formulation that was chosen contained the cytotoxic 
nucleotide analog gemcitabine monophosphate, and 
had previously been published as a monotherapy and 
in combination with siRNA16, 19, 20. In previously 
unpublished experiments from this lab, trace 64Cu was 
encapsulated in the GMP-LCP core via 
co-precipitation and achieved a moderate 
encapsulation efficiency of ~50% because of its 
slightly lower solubility with phosphate when 
compared to calcium (a difference in Ksp of 3-4 orders 
of magnitude). Using PET/CT, we were able to record 
a continuous dynamic scan documenting the first two 
hours after intravenous injection into mice 
(Supplementary Video S1), followed by additional 
time points at 16, 22, and 48 h after injection. As 
shown in Figures 4 and 5A, tumor accumulation of 
64Cu-GMP-LCP reached a maximum at t = 22 h and 
was clearly visible in the PET image. Figure 5A shows 
that while max tumor uptake was sustained 
throughout the study, liver uptake peaked just 20 min 
after injection and showed a continuous decrease over 
time. This time-dependent decrease in liver 
accumulation was not consistent with our 
experiments using 177Lu and 111In, in which liver 
accumulation of the probes remained high after 24 h. 
The difference in 177Lu/111In and 64Cu 
biodistribution is likely because of downstream action 
after the radionuclide cargoes are released from LCP 
via acid-sensitive dissolution in the cellular 
endosome. Because trivalent radiometals like 177Lu are 
not metabolically active, they are not actively excreted 
in the bile and intestines by the liver. When free 
`177LuCl3 is injected intravenously, intestinal 
accumulation of 177Lu is not observed25. In contrast, 
copper is a micronutrient that is actively metabolized 
in the liver, secreted into the bile, and excreted into 
the intestines71. Previously published time-dependent 
PET data of free 64CuCl2 injected intravenously shows 
high initial liver uptake, followed by a decrease in 
liver accumulation via washout through the 
intestines72. Figure 5C similarly shows that as 64Cu is 
excreted from the liver, the intestines begin to show 
64Cu accumulation. Because free 64Cu can only be 
excreted after release from LCP, this may suggest that 
LCP releases its payload within just a few hours of 
deposition.  
Quick copper clearance from off-target organs 
can be desirable if one wants to decrease background 
signal or use copper itself as a theranostic agent72, but 
when using 64Cu as a probe for nanoparticle 
biodistribution, it is important that 64Cu 
pharmacokinetics accurately represent those of the 
nanoparticle. Problematic copper metabolism after 
delivery can be remedied by chelating the copper to 
render it metabolically inactive. For many years, the 
most effective copper chelators were the 
tetraazamacrocyclics DOTA and TETA, which 
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admittedly had well-documented stability issues in 
vivo, allowing 64Cu to transchelate onto 
ceruloplasmin, the main copper-binding enzyme in 
the liver73, 41. The chelator TE2A has shown better 64Cu 
stability than DOTA and TETA, allowing faster and 
more complete off-target clearance in vivo74, 75, and 
recently, a class of bifunctional, bicyclic chelators 
called sarcophagines has shown excellent ability to 
stably chelate copper for tumor imaging76, 77. 
Sarcophagines could potentially be covalently 
attached to the distal ends of PEG or outer leaflet 
lipids on nanoparticles in order to provide stable PET 
imaging. To achieve reproducible results, chelator 
density on the nanoparticle must be optimized, excess 
chelators must be removed before addition of 64Cu, 
and unincorporated 64Cu—if any—must be purified 
away before injection. Alternatively, it may be 
possible to incorporate chelated 64Cu directly into the 
nanoparticle core. A chelator that remains highly 
charged after 64Cu incorporation may co-precipitate 
with calcium phosphate in the LCP core, eliminating 
the need for surface chelation and accurately 
representing the biodistribution of the LCP core while 
also maintaining the metabolic inertness of the 
isotope.  
 
 
Figure 4: PET (left) and PET/CT (right) images of a live athymic nude mouse bearing 
a subcutaneous A549 lung cancer tumor. Images show 2-D coronal sections at t = 22h 
after 64Cu-GMP-LCP administration. Liver and tumor accumulation of 64Cu are both 
clearly visible. Dose of 64Cu = 500 μCi; dose of GMP = 5 mg/kg.  
 
 
Figure 5: Biodistribution kinetics in a live athymic nude mouse 
bearing a subcutaneous A549 lung cancer tumor: (A) 
Quantification of 64Cu from 64Cu-GMP-LCP in liver and tumor, 
calculated from PET reconstruction ROIs; (B) PET images of 2-D 
transverse liver sections at different time points after injection; (C) 
PET images of 2-D coronal tumor sections at different time points 
after injection; (D) 3-D reconstruction of 64Cu biodistribution from 
64Cu-GMP-LCP at different time points after injection. Arrows at 
16 h and 22 h time points show accumulation of 64Cu in the 
intestines. Dose of 64Cu = 500 μCi; dose of GMP = 5 mg/kg.  
 
Future Directions: Magnetic 
Resonance Imaging (MRI) with LCP 
MRI uses the concept of nuclear 
magnetic resonance to reconstruct 
anatomical images. By using a large 
magnet to manipulate the spin and 
magnetic moment of hydrogen atoms in 
the body, and then measuring their 
relaxation times, the distribution and 
structural characteristics of the hydrogen 
atoms can be measured78. MRI contrast 
agents such as iron oxide or gadolinium 
can themselves be magnetized when 
under the influence of an external 
magnetic field, which shortens both the T1 
and T2 relaxation times of nearby 
hydrogen atoms79. Thus, to localize the 
contrast agents, the affected hydrogen 
Tumor
PET             PET/CT
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atoms are measured, and not the contrast agents 
themselves. This requires that a baseline reading be 
completed before adding the contrast agents. 
LCP has not yet been utilized in MRI for any 
purpose, but there are definitely some interesting 
theranostic applications for this imaging modality, 
since gadolinium is another trivalent cation that 
should be easily incorporated into the LCP core. One 
advantage that MRI has over SPECT and PET is that it 
does not use radioactivity to generate an image, 
which makes formulation and optimization of a 
theranostic nanoparticle formulation safer and less 
expensive. What functionally separates gadolinium 
and MRI from SPECT and PET imaging, however, is 
the fact that gadolinium must interact with the 
hydrogen atoms found mostly in water or tissue to 
generate its contrast, unlike radioisotopes that decay 
independent of their surroundings. The magnetic 
moment generated by gadolinium on water decreases 
with distance to the sixth power, which means that 
gadolinium encapsulated in LCP and surrounded by 
calcium phosphate and lipid membrane will provide a 
much lower signal than free or released gadolinium. 
Our previous experiments with 64Cu have provided 
some insight into the release profile of LCP in the 
liver, but using MRI to quantify gadolinium release 
from LCP could show relative release rates in all 
organs, determine if any release occurs in circulation, 
and measure whether the low pH of the tumor does 
indeed cause more rapid LCP dissolution. This type of 
information would not be available if gadolinium 
were chelated to the outside of the particle, as it has 
been repeatedly shown that chelated gadolinium 
retains its ability to magnetize water80, 81. 
This approach can be taken one step further. By 
encapsulating or chelating 64Cu to LCP as described 
above and also encapsulating gadolinium in the core, 
combined PET/MRI could be used to simultaneously 
measure the LCP biodistribution and release, showing 
which organ regions contain both released and 
unreleased LCP over time. This type of information 
could provide insight into what kind of dose the 
tumor and other organs are receiving, as faster release 
of a small molecule drug or siRNA from LCP should 
cause more acute toxicity than slow, sustained release. 
Optical Imaging: Use Caution 
Optical imaging generally uses fluorescent or 
luminescent contrast agents with emission spectrums 
in or near the visible light spectrum. Fluorescent 
compounds require excitation by light before they are 
able to emit light of their own, while other 
luminescent compounds can utilize chemical 
reactions or biological processes to emit light without 
an incident excitation wavelength. The wide range of 
available fluorescent probes and the low cost of 
optical imaging make fluorescent theranostics a very 
desirable modality for both in vitro and in vivo work, 
although attenuation and quenching in vivo can be 
problematic. 
A discussion on fluorescent theranostics has 
been conspicuously missing from this review, in part 
because of a recent article published by the Huang lab 
that has detailed several caveats when dealing with in 
vivo and ex vivo quantification of fluorescent signal82. 
Because of high tissue autofluorescence at lower 
wavelengths in the visible spectrum83, red and 
near-infrared (NIR) probes are extensively used to 
quantify nanoparticle biodistribution. In order to 
determine if these fluorescent probes accurately 
measure nanoparticle accumulation, the referenced 
article compared the biodistribution of LCP using 
three different quantification methods: Texas red 
oligonucleotide fluorescence, 3H-oligonucleotide β 
emission, and 111In γ emission. For consistency, each 
contrast agent was loaded into the LCP core. While 
the biodistributions of 3H and 111In agreed, the high 
amounts of blood in the liver, spleen, and other 
organs quenched and attenuated the fluorescent 
signal in those organs, inaccurately causing 
measurements of higher relative fluorescence in the 
tumor. Even after perfusion to remove circulating 
blood from the liver, fluorescence quenching was not 
completely eliminated. This phenomenon also 
occurred when using a near-infrared dye. The 
quenching occurs at least in part because the 
secondary absorption peaks of hemoglobin and 
oxyhemoglobin present around the red and NIR 
emission spectra absorb the light emitted from the 
fluorescent probes, effectively lowering their signals 
in blood-rich organs such as the liver. Signal 
quenching could also occur because of greater tissue 
thickness of liver vs tumor, but the referenced article 
also compared tissue homogenates to show that equal 
amounts of different tissues will yield different 
fluorescence readings after adding equal 
concentrations of a fluorescent probe. These results 
suggest that while comparing fluorescent signals in 
the same type of organ can provide qualitative results, 
comparing relative fluorescence across different organ 
types, especially when comparing blood-rich organs 
like the liver to sparsely vascularized tumors, is an 
inaccurate quantitative method and should not be 
used unless adequate standards and controls are 
generated. 
Conclusions 
The versatile LCP platform has proven itself to 
be a successful theranostic agent and it is clear that 
there are many more future opportunities for LCP to 
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combine simultaneous therapy and imaging in vivo. 
Our lab has been primarily known as a formulation 
lab, but we have recently focused on innovating upon 
LCP in order to broaden therapeutic approaches and 
learn more about tumor biology. LCP’s success has 
not been based on changes in formulation as much as 
on innovative applications in cancer vaccine therapy, 
gene therapy, and theranostics that provide solutions 
in areas where therapeutic options are lacking. In 
2015, nearly 3,000 peer-reviewed articles were 
published in the field of cancer nanotechnology, and 
many had imaging or theranostic components to aid 
in tumor detection and treatment. It is surely an 
exciting time in this field, as hundreds of minds 
collaborate against cancer, but as competition 
increases, the focus must not be on simply publishing 
novel papers, but on broadening our knowledge of 
cancer and improving treatment options for others.  
Supplementary Material  
Supplementary video S1.  
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